Title : [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].

Pub. Date : 2007 Mar 16

PMID : 17342635






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The synthetic GLP-1 agonist exenatide underlies a different metabolism and has recently been approved by the U.S. Food and Drug Administration for the adjunctive treatment of patients with type 2 diabetes who are suboptimally controlled with metformin and/or sulfonylurea. Metformin glucagon like peptide 1 receptor Homo sapiens